References
- Boemeke L, Bassani L, Marroni CA, et al. Lipid profile in cirrhotic patients and its relation to clinical outcome. Arq Bras Cir Dig. 2015;28(2):132–135.
- Arain SQ, Talpur FN, Channa NA, et al. Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients. Lipids Health Dis. 2017;16(1):51.
- Kroon PA, Powell EE. Liver, lipoproteins and disease: i. Biochemistry of lipoprotein metabolism. J Gastroenterol Hepatol. 1992;7(2):214–224.
- Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020;61(4):470–479.
- Palmer LB, Kuftinec G, Pearlman M, et al. Nutrition in Cirrhosis. Curr Gastroenterol Rep. 2019;21(8):38.
- Bassendine MF, Sheridan DA, Felmlee DJ, et al. HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol. 2011;55(6):1428–1440.
- André P, Perlemuter G, Budkowska A, et al. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis. 2005;25(1):93–104.
- Aizawa Y, Seki N, Nagano T, et al. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol. 2015;21(36):10299–10313.
- Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis. 2004;24(3):289–304.
- Ghadir MR, Riahin AA, Havaspour A, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepatitis Mon. 2010;10(4):285–288.
- Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014;14(4):417–421.
- Janicko M, Veseliny E, Lesko D, et al. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann Hepatol. 2013;12(4):581–587.
- Peng Y, Qi X, Child-Pugh Versus GX. MELD Score for the Assessment of Prognosis in Liver Cirrhosis: a Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95(8):e2877.
- Lippi G, Dipalo M, Musa R, et al. Evaluation of the analytical performances of the novel Beckman Coulter AU5800. Clin Biochem. 2012;45(6):502–504.
- Guidelines for the diagnosis and treatment of liver cirrhosis. Chinese Journal of Hepatology, Chinese Medical Association. 2019;11:846–865.
- Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8(4):453–471.
- Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
- Bassani L, Fernandes SA, Raimundo FV, et al. LIPID PROFILE OF CIRRHOTIC PATIENTS AND ITS ASSOCIATION WITH PROGNOSTIC SCORES: a cross-sectional study. Arq Gastroenterol. 2015;52(3):210–215.
- Tauseef A, Zafar M, Rashid B, et al. Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: a Descriptive Cross-Sectional Study in Tertiary Care Hospital. Cureus. 2020;12(10):e11019.
- Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Physicians India. 2001;49:274–278.
- Jackson AA. Nutrition and Liver Health. Dig Dis. 2017;35(4):411–417.
- Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58(1):325–336.
- Hanai T, Shiraki M, Nishimura K, et al. Free fatty acid as a marker of energy malnutrition in liver cirrhosis. Hepatol Res. 2014;44(2):218–228.
- Nishikawa H, Osaki Y. Liver Cirrhosis: evaluation, Nutritional Status, and Prognosis. Mediators Inflamm. 2015;2015:872152.
- Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23(11):982–989.
- Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology. 2017;65(3):1044–1057.
- Acharya C, Bajaj JS, Microbiota G. Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46(1):155–169.
- Yu Y, Raka F. The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. J Clin Med. 2019;8(12):12.
- Hrabovský V, Mendlová A, Zadák Z, et al. Cholesterol metabolism in acute upper gastrointestinal bleeding, preliminary observations. Wien Klin Wochenschr. 2012;124(23–24):815–821.
- Maharshi S, Sharma BC, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol. 2015;30(10):1507–1513.
- Privitera G, Spadaro L, Marchisello S, et al. Abnormalities of Lipoprotein Levels in Liver Cirrhosis: clinical Relevance. Dig Dis Sci. 2018;63(1):16–26.
- Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol. 2015;21(27):8293–8303.
- He Y, Kothari V, Bornfeldt KE. High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2018;38(2):e10–e6.
- Tosheska Trajkovska K, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol. 2017;18(2):149–154.
- Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–1232.
- Habib A, Mihas AA, Abou-Assi SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol. 2005;3(3):286–291.
- Trieb M, Rainer F, Stadlbauer V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. 2020;73(1):113–120.
- Galbois A, Thabut D, Tazi KA, et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology. 2009;49(1):175–184.
- Guo L, Ai J, Zheng Z, et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem. 2013;288(25):17947–17953.
- Tsai MH, Peng YS, Chen YC, et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J Hepatol. 2009;50(5):906–915.
- Van Der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res. 2014;103(3):362–371.
- Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103(2):219–227.
- Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–1723.
- Gao B, Xiao J, Zhang M, et al. High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: a retrospective study. Lipids Health Dis. 2019;18(1):79.
- Delgado-Coello B, Briones-Orta MA, Macías-Silva M, et al. Cholesterol: recapitulation of its active role during liver regeneration. Liver Int. 2011;31(9):1271–1284.
- Manka P, Olliges V, Bechmann LP, et al. Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure. PLoS One. 2014;9(7):e102351.
- Qi X, Arora A, Tang S, et al. Prognostic Assessment and Management of Liver Cirrhosis. Biomed Res Int. 2017;2017:5326898.
- Wendon J, Bernal W, Willars C, et al. Critical care and cirrhosis: outcome and benefit. Curr Opin Crit Care. 2011;17(5):533–537.
- Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med. 2018;16(1):113.
- Miura K, Ohnishi H. Nonalcoholic fatty liver disease: from lipid profile to treatment. Clin J Gastroenterol. 2012;5(5):313–321.
- Silva VM, Vinagre CG, Dallan LA, et al. Plasma lipids, lipoprotein metabolism and HDL lipid transfers are equally altered in metabolic syndrome and in type 2 diabetes. Lipids. 2014;49(7):677–684.
- Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. Am J Med Sci. 2017;353(3):236–241.
- Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes. 2019;26(2):103–108.
- Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: evidence Report and Systematic Review for the US Preventive Services Task Force. Jama. 2016;316(19):2008–2024.
- Kaplan DE, Serper MA, Mehta R, et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology. 2019;156(6):1693–706.e12.
- Janicko M, Drazilova S, Pella D, et al. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016;22(27):6201–6213.
- Gu Y, Yang X, Liang H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231.
- Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology. 2018;155(5):1564–1577.
- Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47–57.
- Kappus MR. Acute Hepatic Failure and Nutrition. Nutr Clin Pract. 2020;35(1):30–35.
- Gonzáles Yovera JG, Concepción-Zavaleta MJ. Statins in liver cirrhosis in a developing country: benefits overweigh the risk? Expert Opin Drug Saf. 2020;19(12): 1651-2.
- Bosch J, Gracia-Sancho J. Cirrhosis as new indication for statins. Gut. 2020;69(5):953–962.
- Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Curr Treat Options Gastroenterol. 2018;16(2):226–240.